Avantor is one of the companies that we have retained from the 2022 portfolio and the case for buying the company remains. The company is involved every step of the way when supplying products and services to its customers, ranging from scientific discovery to commercial delivery. Essentially, having a presence in the entire value chain, along with high recurring revenues and strong cash flow generation through its customised solutions to clients and its e-commerce platform enables the company to remain profitable and achieve business goals.
Occupying multiple points of the value chain while focused on deleveraging
New York-listed Avantor Inc is a global provider of mission-critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries.
